
    
      Secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease contributes to
      increased cardiovascular morbidity and mortality via different mechanisms. Uncontrolled
      hyperparathyroidism is associated with left ventricular hypertrophy and has been implicated
      in the development of cardiac interstitial fibrosis and diastolic dysfunction.
    
  